Protara Therapeutics is trading 5.7% up today at $4.25 in pre-market, rebounding from a flat-to-slightly-negative week as U.S. equities experience a broader risk-on rally.
- The upward momentum is driven by macro factors, including easing oil prices and reduced concerns regarding potential Federal Reserve interest rate hikes.
- Major indices and futures are trending higher, lifting the stock despite a lack of fresh, company-specific news for the firm.